BioSpace News Archive

Lone Star Bio

Bio-Path Holdings Reports Full Year 2022 Financial Results

Bio-Path Holdings, Inc. announced its financial results for the year ended December 31, 2022 and provided an update on recent corporate developments.

March 31, 2023
·
5 min read
Business

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

BioCryst Pharmaceuticals, Inc. announced the appointment of Dr. Nancy Hutson as chair of its board of directors, effective immediately.

March 31, 2023
·
2 min read
Pharm Country

Milestone Scientific Provides 2022 Year-End Business Update

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, provided a business update and announced financial results for the year ending December 31, 2022.

March 31, 2023
·
8 min read
Pharm Country

Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems.

March 31, 2023
·
3 min read
Nordic Nanovector - Annual General Meeting Postponed

The Board of Directors of Nordic Nanovector ASA has decided to postpone the upcoming Annual General Meeting, which was originally scheduled for 26 April.

March 31, 2023
·
1 min read
Drug Development

Eisai publishes additional detailed analyses from lecanemab phase 2b study

BioArctic AB’s partner Eisai announced the publication of additional detailed analyses from the phase 2b clinical study, evaluating the efficacy and safety of lecanemab for mild cognitive impairment due to Alzheimer’s disease and mild AD.

March 31, 2023
·
10 min read
Business

Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates.

March 31, 2023
·
11 min read
Biotech Bay

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 31, 2023

IDEAYA Biosciences, Inc. announced that, on March 30, 2023, the Compensation Committee of IDEAYA’s Board of Directors granted non-qualified stock options to purchase an aggregate of 79,700 shares of the Company’s common stock to two newly hired employees.

March 31, 2023
·
2 min read